Cargando…

Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone

PURPOSE: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards. METHODS: A PDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Shillington, Alicia C, Col, Nananda, Bailey, Robert A, Jewell, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425316/
https://www.ncbi.nlm.nih.gov/pubmed/25995622
http://dx.doi.org/10.2147/PPA.S82555
_version_ 1782370469953929216
author Shillington, Alicia C
Col, Nananda
Bailey, Robert A
Jewell, Mark A
author_facet Shillington, Alicia C
Col, Nananda
Bailey, Robert A
Jewell, Mark A
author_sort Shillington, Alicia C
collection PubMed
description PURPOSE: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards. METHODS: A PDA was developed by a multidisciplinary steering committee of clinicians, patient advocate, nurse, certified diabetes educators, and decision scientist, using a systematic development process. The process included defining the PDA scope and purpose, outlining the framework, content creation, and designing for integration into clinical practice. This was accomplished through a review of the literature and publically available educational materials and input from practicing clinicians and patients during development and iteratively refining content based on input. Patients with poorly controlled T2DM on metformin considering additional medication assessed the PDA during a pilot. RESULTS: Testing identified six preference-sensitive domains important for choosing T2DM treatment: degree of glycemic response, avoiding weight gain, hypoglycemia risk and other adverse events, avoiding injections, convenience of dose administration, blood glucose monitoring, and cost of therapy. Patient feedback guided content revision. Treatment options were offered after presenting medication class risk–benefit information and eliciting patient values, goals, and preferences. The PDA received the highest International Patient Decision Aids Standards global score to date, 88/100, with 100% of criteria fully met for the following dimensions: development process, disclosures, evaluation process, evidence quality, guidance for users, information quality, language/readability, testing, and eliciting patient values. CONCLUSION: A PDA was developed to help T2DM patients make decisions regarding medication choice. This approach may be applicable to other chronic conditions.
format Online
Article
Text
id pubmed-4425316
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44253162015-05-20 Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone Shillington, Alicia C Col, Nananda Bailey, Robert A Jewell, Mark A Patient Prefer Adherence Methodology PURPOSE: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards. METHODS: A PDA was developed by a multidisciplinary steering committee of clinicians, patient advocate, nurse, certified diabetes educators, and decision scientist, using a systematic development process. The process included defining the PDA scope and purpose, outlining the framework, content creation, and designing for integration into clinical practice. This was accomplished through a review of the literature and publically available educational materials and input from practicing clinicians and patients during development and iteratively refining content based on input. Patients with poorly controlled T2DM on metformin considering additional medication assessed the PDA during a pilot. RESULTS: Testing identified six preference-sensitive domains important for choosing T2DM treatment: degree of glycemic response, avoiding weight gain, hypoglycemia risk and other adverse events, avoiding injections, convenience of dose administration, blood glucose monitoring, and cost of therapy. Patient feedback guided content revision. Treatment options were offered after presenting medication class risk–benefit information and eliciting patient values, goals, and preferences. The PDA received the highest International Patient Decision Aids Standards global score to date, 88/100, with 100% of criteria fully met for the following dimensions: development process, disclosures, evaluation process, evidence quality, guidance for users, information quality, language/readability, testing, and eliciting patient values. CONCLUSION: A PDA was developed to help T2DM patients make decisions regarding medication choice. This approach may be applicable to other chronic conditions. Dove Medical Press 2015-04-30 /pmc/articles/PMC4425316/ /pubmed/25995622 http://dx.doi.org/10.2147/PPA.S82555 Text en © 2015 Shillington et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Methodology
Shillington, Alicia C
Col, Nananda
Bailey, Robert A
Jewell, Mark A
Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title_full Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title_fullStr Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title_full_unstemmed Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title_short Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
title_sort development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425316/
https://www.ncbi.nlm.nih.gov/pubmed/25995622
http://dx.doi.org/10.2147/PPA.S82555
work_keys_str_mv AT shillingtonaliciac developmentofapatientdecisionaidfortype2diabetesmellitusforpatientsnotachievingglycemiccontrolonmetforminalone
AT colnananda developmentofapatientdecisionaidfortype2diabetesmellitusforpatientsnotachievingglycemiccontrolonmetforminalone
AT baileyroberta developmentofapatientdecisionaidfortype2diabetesmellitusforpatientsnotachievingglycemiccontrolonmetforminalone
AT jewellmarka developmentofapatientdecisionaidfortype2diabetesmellitusforpatientsnotachievingglycemiccontrolonmetforminalone